Summary
Signal counts
Assets tracked: 4
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
Georgetown University
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07645326 | https://clinicaltrials.gov/study/NCT01888965 | https://clinicaltrials.gov/study/NCT01262027 | https://clinicaltrials.gov/study/NCT07592767 | https://clinicaltrials.gov/study/NCT03467867 | https://clinicaltrials.gov/study/NCT05841771
Assets
Linked programs
- Androgen Deprivation Therapy (ADT): Low Signal (0/5)
- Dovitinib: Registry Stop Signal (4/5)
- Trans-Resveratrol: Low Signal (0/5)
- Venetoclax: Timeline Staleness Signal (3/5)